Susan, I can't speak for the stock price, but in terms of clinical trial, phase I is meant to test for unwanted side effects only. So the 5 our of 9 is a bonus. The efficacy of the treatment will be tested in phase III. Furthermore, when testing the efficacy, the treatment is either tested against a placebo or against the best currently available treatment. So with the poor treatment options available for melanoma as of now, it is not difficult for such a drug to be approved for commercial sale.
You may have seen it all, but you really don't understand any of what you've seen, which makes it pointless.
"This company isn't going anywhere in the long run." If you put "short" in place of "long", then I would agree. Because, as others have said, phase I to FDA approval is at least several years apart. Long run though, you just can't say. But I agree that capital raising is on the cards, it is just a matter of when. They need money for phase II.
VLA Price at posting:
$1.20 Sentiment: None Disclosure: Not Held
